MiStent Sirolimus Eluting Absorbable Coronary Stent trial results

Positive data from two clinical studies of MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System indicates that it may provide an innovative treatment option for patients suffering from Coronary Artery Disease. Eighteen-month outcomes from the DESSOLVE I trial show mean in-stent late lumen loss (LLL) was essentially unchanged through 18 months post-procedure in patients with discrete de novo lesions in native coronary arteries. In nine-month data supporting all study endpoints in the DESSOLVE II trial, the MiStent SES demonstrated statistically superior performance as compared to the Endeavor Sprint DES (Endeavor) for the primary endpoint of in-stent LLL. At nine months' follow-up, in-stent LLL was 0.27 mm with a target lesion revascularization (TLR) rate of 0.9%. The MACE rates were 4.3% for MiStent SES and 6.7% for Endeavor. Results were presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.